An academic partnership to improve diversity in clinical trials has drafted its first industry team members. | An academic ...

Merck (MRK) reachead $117.17 at the closing of the latest trading day, reflecting a -0.05% change compared to its last close.

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

Merck's Keytruda scored two important victories in women's cancer, according to presentations Sunday at the ESMO meeting.

MWINYI, The First Lady of the Zanzibar Senator, Dr. Rasha Kelej, CEO of Merck Foundation and Chairperson of Merck Foundation Africa Asia Luminary shared, "We are excited to announce the 11th Edition ...

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

In the closing of the recent trading day, Merck (MRK) stood at $117.23, denoting a -1.19% change from the preceding trading day.

Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to ...

Merck ($MRK) continues to solidify its position in cancer treatment as its top-selling drug Keytruda delivers outstanding ...

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative ...

The recipients of the Merck Animal Health Bovine Veterinary Student Recognition Award were selected based on their academic ...

A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...